<div id="readability-page-1"><p>Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) shares crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $22.32 and traded as high as $23.75. Capricor Therapeutics shares last traded at $23.52, with a volume of 603,063 shares trading hands.</p><div><p><span></span><span>Get <strong>Capricor Therapeutics</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><ul><li>Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher</li></ul><p>CAPR has been the subject of a number of research analyst reports. Roth Mkm increased their price objective on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, November 11th. Industrial Alliance Securities  set a $48.00 price target on Capricor Therapeutics in a research note on Wednesday, December 3rd. HC Wainwright lifted their price objective on Capricor Therapeutics from $24.00 to $60.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, December 3rd. Maxim Group boosted their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 4th. Finally, Oppenheimer increased their target price on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, December 8th. Nine research analysts have rated the stock with a Buy rating and one  has issued  a Sell rating to the stock. According to MarketBeat.com, Capricor Therapeutics currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $40.82.</p><p><b>View Our Latest Stock Analysis on Capricor Therapeutics</b></p><h2>Capricor Therapeutics Stock Performance</h2><p>The business has a 50-day simple moving average of $22.32 and a 200-day simple moving average of $12.26. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -13.07 and a beta of 0.22. </p><p>Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54).  Research analysts anticipate that  Capricor Therapeutics, Inc. will post -1.21 EPS for the current year. </p><h2>Institutional Inflows and Outflows</h2><p>Several large investors have recently modified their holdings of CAPR. Geode Capital Management LLC lifted its holdings in shares of  Capricor Therapeutics by 6.8% in the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company's stock valued at $9,565,000 after purchasing an additional 61,701 shares during the last quarter.  Pier Capital LLC lifted its position in  Capricor Therapeutics by 35.0% during the 3rd quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company's stock worth $3,580,000 after acquiring an additional 128,837 shares during the period.  Goldman Sachs Group Inc. increased its stake in  Capricor Therapeutics by 39.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company's stock valued at $3,902,000 after buying an additional 116,373 shares during the period.  Two Sigma Investments LP raised its stake in shares of  Capricor Therapeutics by 128.3% during the 3rd quarter. Two Sigma Investments LP now owns 355,796 shares of the biotechnology company's stock worth $2,565,000 after buying an additional 199,959 shares in the last quarter.  Finally, Jump Financial LLC lifted its stake in shares of  Capricor Therapeutics by 42.6% in the second quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company's stock valued at $2,309,000 after purchasing an additional 69,515 shares during the period. Institutional investors and hedge funds own  21.68% of the company's stock. </p><h2>About Capricor Therapeutics</h2> (Get Free Report)<p>Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.  </p><p>The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.</p><h2>Read More</h2><ul><li>Five stocks we like better than Capricor Therapeutics</li><li>America's Next Power Move Starts Underground</li><li>Your Signature Is Missing – Act Before It’s Too Late</li><li>URGENT: Trump Just Triggered AI’s Biggest Disruption Yet</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>BSEM: A $25.50 Price Target, and Nasdaq on the Horizon!</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Capricor Therapeutics Right Now?</h2><p>Before you consider Capricor Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.</p><p>While Capricor Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

<p>Capricor Therapeutics (NASDAQ:CAPR) shares have crossed above their 50-day moving average of $22.32, trading at $23.52 with a volume of 603,063 shares. Analysts have raised their price targets, with Roth Mkm setting it at $13.00 and HC Wainwright at $60.00. The stock has a market cap of $1.08 billion and a P/E ratio of -13.07. Institutional investors hold 21.68% of the stock. Capricor focuses on cell and exosome-based therapeutics for cardiovascular and rare diseases, with its lead candidate, CAP-1002, in clinical trials for DMD and COVID-19-related heart injury.</p>

Market Beat

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Pharma

Proshares UltraShort Nasdaq Biotech

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

VG Health

Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50 Day Moving Average   - Should You Sell?